Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Recursion Pharmaceuticals Inc. stock reached a new 52-week low, closing at $3.53, just pennies away from its absolute 52-week bottom of $3.54. This milestone marks a significant downturn for the ...
Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached its second release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results